>
細(xì)胞CELL>
ATCC腫瘤細(xì)胞>
SNU-387
運(yùn)輸方式:凍存運(yùn)輸
是否是腫瘤細(xì)胞:1
物種來源:人
生長(zhǎng)狀態(tài):貼壁生長(zhǎng)
年限:grade IV/V
數(shù)量:大量
器官來源:肝
ATCC Number:CRL-2237?
相關(guān)疾?。浩渌膊?br />
細(xì)胞形態(tài):上皮樣
規(guī)格:100 ul Designations: SNU-387
Depositors: ?J Park
Biosafety Level:2 [CELLS CONTAIN HEPATITIS B VIRUS ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: liver
Tumor Stage: grade IV/V
Disease: pleomorphic hepatocellular carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).
Isolation: Isolation date: 1990
Antigen Expression:Blood Type O; Rh +
DNA Profile (STR):Amelogenin: X
CSF1PO: 13,14
D13S317: 12
D16S539: 9
D5S818: 10,12
D7S820: 8,10
THO1: 7
TPOX: 8,9
vWA: 14,16
Cytogenetic Analysis:aneuploid; modal number = 67
Age: 41 years
Gender: female
Ethnicity: Asian
Comments:SNU-387 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum.
After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum.
Grossly, the original tumor was single nodular.
Histologically, it was predominantly compact and minor trabecular type.
The cultured cells contain a single nucleus.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0℃
Subculturing: Protocol:
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 61 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080